Liza Gill1, Allison Zarbo2, Prescilia Isedeh3, Gordon Jacobsen4, Henry W Lim3, Iltefat Hamzavi5. 1. College of Human Medicine, Michigan State University, East Lansing, Michigan. 2. Wayne State University School of Medicine, Detroit, Michigan. 3. Vitiligo Research and Treatment Center, Department of Dermatology, Henry Ford Hospital, Detroit, Michigan. 4. Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan. 5. Vitiligo Research and Treatment Center, Department of Dermatology, Henry Ford Hospital, Detroit, Michigan. Electronic address: ihamzav1@hfhs.org.
Abstract
BACKGROUND: Few large-scale studies have quantified the burden of comorbid autoimmune diseases in patients with vitiligo. OBJECTIVE: We sought to determine the prevalence of comorbid autoimmune diseases in patients with vitiligo. METHODS: We conducted a manual chart review on a cohort of 1873 patients with vitiligo seen between January 2002 and October 2012 at the Henry Ford Health System in Detroit, MI. Patients were excluded if they had fewer than 2 dermatology notes (N = 595) or if they were never given a diagnosis of vitiligo by a dermatologist (N = 180). RESULTS: Of 1098 patients with vitiligo, nearly 20% had at least 1 comorbid autoimmune disease. Compared with the general US population, we found a higher prevalence of thyroid disease (12.9%, P < .001), alopecia areata (3.8%, P < .001), inflammatory bowel disease (0.9%, P = .046), pernicious anemia (0.5%, P = .007), systemic lupus erythematosus (0.3%, P = .048), Guillain-Barre syndrome (0.3%, P < .001), discoid lupus (0.2%, P = .003), linear morphea (0.2%, P < .001), myasthenia gravis (0.2%, P = .002), and Sjögren syndrome (0.2%, P = .011). LIMITATIONS: The study lacked a control group. This was a single-institution study with possible selection bias, and thus the findings may not be representative of the overall population of patients with vitiligo. CONCLUSIONS: We observed a high prevalence of comorbid autoimmune diseases in patients with vitiligo and report several new associations.
BACKGROUND: Few large-scale studies have quantified the burden of comorbid autoimmune diseases in patients with vitiligo. OBJECTIVE: We sought to determine the prevalence of comorbid autoimmune diseases in patients with vitiligo. METHODS: We conducted a manual chart review on a cohort of 1873 patients with vitiligo seen between January 2002 and October 2012 at the Henry Ford Health System in Detroit, MI. Patients were excluded if they had fewer than 2 dermatology notes (N = 595) or if they were never given a diagnosis of vitiligo by a dermatologist (N = 180). RESULTS: Of 1098 patients with vitiligo, nearly 20% had at least 1 comorbid autoimmune disease. Compared with the general US population, we found a higher prevalence of thyroid disease (12.9%, P < .001), alopecia areata (3.8%, P < .001), inflammatory bowel disease (0.9%, P = .046), pernicious anemia (0.5%, P = .007), systemic lupus erythematosus (0.3%, P = .048), Guillain-Barre syndrome (0.3%, P < .001), discoid lupus (0.2%, P = .003), linear morphea (0.2%, P < .001), myasthenia gravis (0.2%, P = .002), and Sjögren syndrome (0.2%, P = .011). LIMITATIONS: The study lacked a control group. This was a single-institution study with possible selection bias, and thus the findings may not be representative of the overall population of patients with vitiligo. CONCLUSIONS: We observed a high prevalence of comorbid autoimmune diseases in patients with vitiligo and report several new associations.
Authors: Tina Kiguradze; Finola M Bruins; Nicholas Guido; Tanya Bhattacharya; Alfred Rademaker; Aleksandra G Florek; Alba Posligua; Shatil Amin; Anne E Laumann; Dennis P West; Beatrice Nardone Journal: Int J Dermatol Date: 2017-02-19 Impact factor: 2.736
Authors: Isabell Cordts; Nicolas Bodart; Kathi Hartmann; Katerina Karagiorgou; John S Tzartos; Lin Mei; Jens Reimann; Philip Van Damme; Michael H Rivner; Alain Vigneron; Joachim Weis; Jörg B Schulz; Socrates J Tzartos; Kristl G Claeys Journal: J Neurol Date: 2017-05-17 Impact factor: 4.849